vaxigriptetra suspenzija za injiciranje v napolnjeni injekcijski brizgi
ha seva b/phuket/3073/2013, divji tip, podoben sevu b/phuket/3073/2013; ha seva a/darwin/9/2021, ivr-228, podoben sevu a/darwin/9/2021 (h3n2); ha seva b/michigan/01/2021, divji tip, podoben sevu b/austria/1359417/2021; ha seva a/victoria/2897/2022, ivr-238, podoben sevu a/victoria/4897/2022 (h1n1)p - suspenzija za injiciranje - ha seva b/phuket/3073/2013, divji tip, podoben sevu b/phuket/3073/2013 15 µg / 1 brizga ha seva a/darwin/9/2021, ivr-228, podoben sevu a/darwin/9/2021 (h3n2)15 µg / 1 brizga ha seva b/michigan/01/2021, divji tip, podoben sevu b/austria/1359417/202115 µg / 1 brizga ha seva a/victoria/2897/2022, ivr-238, podoben sevu a/victoria/4897/2022 (h1n1)p15 µg / 1 brizga; ha seva a/darwin/9/2021, ivr-228, podoben sevu a/darwin/9/2021 (h3n2) 15 µg / 1 brizga ha seva b/michigan/01/2021, divji tip, podoben sevu b/austria/1359417/202115 µg / 1 brizga ha seva a/victoria/2897/2022, ivr-238, podoben sevu a/victoria/4897/2022 (h1n1)p15 µg / 1 brizga; ha seva b/michigan/01/2021, divji tip, podoben sevu b/austria/1359417/2021 15 µg / 1 brizga ha seva a/victoria/2897/2022, ivr-238, podoben sevu a/victoria/4897/2022 (h1n1)p15 µg / 1 brizga; ha seva a/victoria/2897/2022, ivr-238, podoben sevu a/victoria/4897/2022 (h1n1)p - cepivo proti gripi, z delci virusov ali s površinskimi antigeni, inaktivirano
vaxigriptetra suspenzija za injiciranje v napolnjeni injekcijski brizgi
ha seva b/phuket/3073/2013, divji tip, podoben sevu b/phuket/3073/2013; ha seva a/darwin/9/2021, ivr-228, podoben sevu a/darwin/9/2021 (h3n2); ha seva b/michigan/01/2021, divji tip, podoben sevu b/austria/1359417/2021; ha seva a/victoria/2897/2022, ivr-238, podoben sevu a/victoria/4897/2022 (h1n1)p - suspenzija za injiciranje - ha seva b/phuket/3073/2013, divji tip, podoben sevu b/phuket/3073/2013 15 µg / 1 brizga ha seva a/darwin/9/2021, ivr-228, podoben sevu a/darwin/9/2021 (h3n2)15 µg / 1 brizga ha seva b/michigan/01/2021, divji tip, podoben sevu b/austria/1359417/202115 µg / 1 brizga ha seva a/victoria/2897/2022, ivr-238, podoben sevu a/victoria/4897/2022 (h1n1)p15 µg / 1 brizga; ha seva a/darwin/9/2021, ivr-228, podoben sevu a/darwin/9/2021 (h3n2) 15 µg / 1 brizga ha seva b/michigan/01/2021, divji tip, podoben sevu b/austria/1359417/202115 µg / 1 brizga ha seva a/victoria/2897/2022, ivr-238, podoben sevu a/victoria/4897/2022 (h1n1)p15 µg / 1 brizga; ha seva b/michigan/01/2021, divji tip, podoben sevu b/austria/1359417/2021 15 µg / 1 brizga ha seva a/victoria/2897/2022, ivr-238, podoben sevu a/victoria/4897/2022 (h1n1)p15 µg / 1 brizga; ha seva a/victoria/2897/2022, ivr-238, podoben sevu a/victoria/4897/2022 (h1n1)p - cepivo proti gripi, z delci virusov ali s površinskimi antigeni, inaktivirano
vumerity
biogen netherlands b.v. - diroximel fumarate (biib098) - multiplo sklerozo, recidivno-nakazila - imunosupresivi - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).
dimethyl fumarate mylan
mylan ireland limited - dimetil fumarat - multiplo sklerozo, recidivno-nakazila - imunosupresivi - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate polpharma
zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetil fumarat - multiplo sklerozo, recidivno-nakazila - imunosupresivi - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.
dimethyl fumarate teva
teva gmbh - dimetil fumarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
dimethyl fumarate accord
accord healthcare s.l.u. - dimetil fumarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresivi - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
genotropin 5,3 mg/ml prašek in vehikel za raztopino za injiciranje
pfizer luxembourg sarl - somatropin, rekombinantni - prašek in vehikel za raztopino za injiciranje - somatropin, rekombinantni 5,3 mg / 1 vložek - somatropin
genotropin 12 mg/ml prašek in vehikel za raztopino za injiciranje
pfizer luxembourg sarl - somatropin, rekombinantni - prašek in vehikel za raztopino za injiciranje - somatropin, rekombinantni 12 mg / 1 vložek - somatropin
genotropin 12 mg/ml prašek in vehikel za raztopino za injiciranje
pfizer luxembourg sarl - somatropin, rekombinantni - prašek in vehikel za raztopino za injiciranje - somatropin, rekombinantni 12 mg / 1 vložek - somatropin